MEDICA 2023: Introducing Pluslife's Latest Innovation in Veterinary Diagnostic Technology

Pluslife is currently showcasing its Next-Generation Molecular POCT Solutions at MEDICA, the largest international exhibition for the medical and healthcare sector. Known for its innovative POC molecular diagnostic system, Pluslife invites visitors to witness firsthand how Pluslife's cutting-edge technology is revolutionizing medical and veterinary diagnostics at the forefront of the industry. Join Pluslife at Hall 3, Booth 3K92-11, and meet Pluslife’s CEO Mr. Chong Chen and our team.

As the weather cools down in the northern hemisphere and respiratory viruses like SARS-CoV-2, influenza, and RSV surge, Pluslife addresses the challenges of respiratory infections during flu season by offering a variety of single and combo pathogen detection test cards, including SARS-CoV-2/Flu A/Flu B test card and RSV/Flu A/Flu B test card. With Pluslife's palm-sized molecular POCT system, the Mini Dock, tests become easy and user-friendly, with test result accuracy comparable to PCR. This innovation eliminates the necessity for cold-chain storage or pipetting, even allowing for at-home operation by non-physicians.

For test centers and hospitals with high test volume, Pluslife Dock Pro 8 is tailored to application scenarios of professional healthcare institutions, with integrated functions including barcode reader, result printing, and LIS system. At the MEDICA exhibition, Pluslife is unveiling the Dock Pro 8 for veterinary diagnosis for the first time, introducing a brand-new diagnostic option for pet hospitals and clinics. Pluslife Dock Pro 8 for veterinary diagnosis is compatible with both canine and feline pathogen tests, featuring 8 independent test channels for efficient and accurate diagnostics in veterinary care.

In terms of pet diagnostics, Pluslife continues to expand its pet test panel by developing new pathogen tests. In addition to the canine CRQ test card and feline FCM test card, Pluslife has recently introduced its new canine parvovirus (CPV) test card. Early detection of CPV is crucial for effective treatment, and Pluslife's CPV test seamlessly combines the speed of antigen detection with the precision of PCR testing, enabling rapid and accurate diagnostics that increase the chances of recovery.

Pluslife is committed to continuously advancing molecular POCT technology, aligning with our company's mission of consistently delivering accurate and rapid molecular POC solutions to enhance the lives of both humans and animals. We are actively seeking partnerships on a global scale, and we invite you to stay tuned for our upcoming exhibitions and events next year.